

Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

<b>Trial Status</b> Recruiting	<b>Trial Runs In</b> 3 Countries	<b>Trial Identifier</b> NCT05927571 2023-504657-13-00 GO43979
-----------------------------------	-------------------------------------	---

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

*Trial Summary:*

The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II dose (RP2D) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

<b>Genentech, Inc.</b> Sponsor	<b>Phase 1</b> Phase
NCT05927571 2023-504657-13-00 GO43979 Trial Identifiers	

*Eligibility Criteria:*

<b>Gender</b> All	<b>Age</b> ≥18 Years	<b>Healthy Volunteers</b> No
----------------------	-------------------------	---------------------------------